Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 30 days matching "ALS"

PipelineRSSMay 13

FDA puts injection therapy COYA 302 on fast track for treating ALS

The FDA has given special fast-track status to COYA 302, an injection treatment being developed by Coya Therapeutics for ALS (a disease that weakens muscles over time). Early testing showed it might slow down how quickly the disease gets worse in a small group of patients. Fast-track status means the FDA will review this treatment more quickly than usual to help get it to patients faster.

WHY IT MATTERSALS patients now have a potential new treatment option moving through FDA review faster than standard timelines, which could mean access to COYA 302 years sooner if clinical trials continue to show benefit.
💬 Ask your doctoramyotrophic lateral sclerosis
PipelineRSSMay 7

ALS treatment tazbentetol gets FDA fast track status

The FDA has given fast-track status to tazbentetol, a new oral medication being developed by Spinogenix for ALS (a disease that affects nerve cells that control muscles). Fast-track status means the FDA will review this drug more quickly and the company can talk with FDA regulators more often during development. This designation is given to treatments for serious diseases where there aren't many good options available.

WHY IT MATTERSFast-track designation could bring tazbentetol to ALS patients 1-2 years sooner than standard FDA review timelines, which is critical since ALS progresses rapidly and patients have limited treatment options.
👁 Watch this spaceamyotrophic lateral sclerosis
PipelineRSSMay 5

Clene plans CNM-Au8 filing for accelerated approval in ALS

A company called Clene is planning to ask the FDA to approve a new drug called CNM-Au8 for treating ALS, a disease that affects nerve cells and causes muscle weakness. The company met with the FDA and decided to use a faster approval process called accelerated approval, which can get promising treatments to patients more quickly than the standard process.

WHY IT MATTERSIf CNM-Au8 receives accelerated approval, ALS patients could gain access to a new treatment option sooner than through the standard FDA review timeline, potentially slowing disease progression.
👁 Watch this spaceAmyotrophic Lateral Sclerosis

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases